Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis

Olivier Morel; Antoine Faure; Patrick Ohlmann; Laurence Jesel; Dominique Desprez; Lelia Grunebaum; Pierre Bareiss

doi:10.1160/TH07-03-0188

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(04): 896-899
DOI: 10.1160/TH07-03-0188

Case Report

Schattauer GmbH

Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis

Authors

Olivier Morel

¹Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France

²Institut d’hématologie et d’Immunologie, Faculté de Médecine, Strasbourg et Unité 770 INSERM, France
Antoine Faure

¹Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France
Patrick Ohlmann

¹Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France
Laurence Jesel

¹Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France
Dominique Desprez

³Unité d’Hémostase, CH Strasbourg, France
Lelia Grunebaum

³Unité d’Hémostase, CH Strasbourg, France
Pierre Bareiss

¹Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, France

Abstract

Full Text

References

References
1 Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-1987.
2 Ajzenberg N, Aubry P, Huisse MG. et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005; 45: 1753-1756.
3 Barragan P, Bouvier JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
4 Wenaweser P, Dorffler-Melly J, Imboden K. et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-1752.
5 Schafer A, Bonz AW, Eigenthaler M. et al. Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function?. Thromb Haemost 2007; 97: 862-865.
6 von Beckerath N, Taubert D, Pogatsa-Murray G. et al. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 2005; 93: 789-791.
7 Biondi-Zoccai GGE, Sangiogri GM, Chieffo A. et al. Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol 2005; 95: 1466-1468.
8 Kuchulakanti PK, Chu WW, Torguson R. et al. Correlates and long term outcomes of angiographically proven stent thrombosis with sirolimus and paclitaxeleluting stents. Circulation 2006; 111: 1108-1113.
9 Smit JJ, van’t Hof AW, de Boer MJ. et al. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 2006; 96: 190-195.
10 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004; 16: 169-174.
11 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
12 Aleil B, Meyer N, Cazenave JP. et al. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005; 94: 886-887.
13 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
14 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
15 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
16 Cuisset T, Frere C, Quilici J. et al. High post-tratment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 3: 542-549.
17 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
18 Gurbel PA, Bliden KP, Samara WM. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 2005; 46: 1827-1832.
19 Obergfell A, Strotmann J, Bonz A. et al. Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis. Thromb Haemost 2004; 92: 1446-1447.
20 Buonamici P, Marucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
21 Labarthe B, Théroux P, Angioï M. et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638-645.
22 Malinin A, Pokov A, Spergling M. et al. Monitoring Platelet inhibition after clopidogrel with the verifyNow- P2Y12 rapide analyser: the verify thrombosis risk assessment (VERITAS) study. Thromb Res 2006; 119: 277-284.
23 Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006; 19: 439-448.
24 Siller-Matula J, Schror K, Wojta J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
25 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
26 Schwarz UR, Geiger J, Walter U. et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
27 Aleil B, Ravanat C, Cazenave JP. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
28 Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
29 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 17: 2126-2130.
30 Hacquard M, Angioi M, Lecompte T. et al. Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion ‘resistant’ to treatment?. Ann Pharm Fr 2007; 65: 169-173.